Nuvalent (NUVL) TD Cowen's 6th Annual Oncology Innovation Summit summary

Key data updates and disclosure plans

• Top line pivotal data for TKI pretreated ROS1 patients will be released in the first half of the year via a standalone press release, with full data to follow at a future medical meeting.

• The upcoming data set will focus on previously treated ROS1 non-small cell lung cancer patients, with broad inclusion criteria covering various prior therapies and disease characteristics.

• Phase II cohorts for both TKI naive and previously treated patients have been over-enrolled, with 430 patients total and 330 in Phase II as of December last year.

• Data will be assessed using blinded independent central review, a more stringent standard than prior investigator-assessed Phase I data.

• Plans for presenting full data at a medical conference are under consideration, with updates expected in the second half of the year.

Clinical and regulatory strategy

• The filing strategy prioritizes previously treated ROS1 patients, with the potential to update filings as first-line data matures.

• All NDA preparation components, including non-clinical and manufacturing data, are underway to enable rapid submission once clinical data is available.

• Regulatory interactions are ongoing, with breakthrough designation already granted for later-line ROS1 and ALK indications.

• The company is open to leveraging all available regulatory pathways to expedite approvals but will tailor strategies based on emerging data and regulator feedback.

• For ALK, both second and third line data are expected later this year, with a randomized front-line study (Alcazar) comparing to Alectinib planned.

Product differentiation and market opportunity

• Zidesamtinib aims to address limitations of current ROS1 therapies by offering brain penetrance, activity against resistance mutations, and a favorable safety profile.

• The drug is positioned as potentially suitable for all ROS1 patients, regardless of treatment line, and is differentiated from dual TRK/ROS1 inhibitors by minimizing CNS adverse events.

• Commercial opportunity is seen as significant, with reference to crizotinib's $400M sales and the potential to outperform due to improved efficacy and tolerability.

• Pricing strategy for Zidesamtinib will consider recent market precedents but remains undecided pending pivotal data.

• In ALK, Neladalkib is designed to overcome resistance and CNS limitations of current therapies, aiming for durable responses in both second and third line settings.